Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan.
Department of Gastroenterological Surgery, Kariya Toyota General Hospital, Kariya, Aichi 448‑8505, Japan.
Oncol Rep. 2023 Mar;49(3). doi: 10.3892/or.2023.8489. Epub 2023 Feb 3.
Ataxia telangiectasia and Rad3‑related (ATR) is a kinase that repairs DNA damage. Although inhibitors that selectively target ATR have been developed, their effectiveness in colorectal cancer has not been widely reported. The present study hypothesized that anticancer agents that effectively act in the S phase before the G/M checkpoint may be ideal agents for concomitant use with ATR inhibitors, which act at the G/M checkpoint. Therefore, the present study examined the combined effects of AZD6738, an ATR inhibitor, and trifluridine (FTD), which acts in the S phase and has a high DNA uptake rate. cell viability assays, flow cytometry and western blotting were performed to evaluate cell viability, and changes in cell cycle localization and protein expression. The results revealed that in colorectal cancer cells, the combination of AZD6738 and FTD inhibited cell viability, cell cycle arrest at the G/M checkpoint and Chk1 phosphorylation, and increased apoptotic protein expression levels more than that when treated with FTD alone. HT29, a BRAF‑mutant cell line known to be resistant to anticancer drugs, was used to induce tumors . Since FTD does not have sufficient efficacy when administered orally, it was mixed with tipiracil to prevent degradation; this mixture is known as TAS‑102. TAS‑102 alone exerted minimal tumor suppressive effects; however, when used in combination with AZD6738, tumor suppression was observed, suggesting that AZD6738 may increase the effectiveness of a weakly effective drug. Although ATR inhibitors are effective against p53 mutants, the present study demonstrated that these inhibitors were also effective against the p53 wild‑type HCT116 colorectal cancer cell line. In conclusion, combination therapy with AZD6738 and FTD enhanced the inhibition of tumor proliferation and . In the future, we aim to investigate the potentiating effect of AZD6738 on 5‑fluouracil‑resistant cell lines that are difficult to treat.
毛细血管扩张共济失调症和 Rad3 相关蛋白(ATR)是一种修复 DNA 损伤的激酶。尽管已经开发出了选择性靶向 ATR 的抑制剂,但它们在结直肠癌中的疗效尚未得到广泛报道。本研究假设,在 G2/M 检查点之前的 S 期有效作用的抗癌剂可能是与在 G2/M 检查点作用的 ATR 抑制剂联合使用的理想药物。因此,本研究检测了 ATR 抑制剂 AZD6738 与氟尿苷(FTD)联合使用的效果,氟尿苷在 S 期起作用且具有高 DNA 摄取率。通过细胞活力测定、流式细胞术和 Western blot 检测来评估细胞活力以及细胞周期定位和蛋白表达的变化。结果显示,在结直肠癌细胞中,AZD6738 与 FTD 的联合用药抑制了细胞活力,使细胞在 G2/M 检查点停滞,并使 Chk1 磷酸化增加,促进了凋亡蛋白的表达水平,其效果强于单独使用 FTD。HT29 是一种已知对抗癌药物具有耐药性的 BRAF 突变细胞系,用于诱导肿瘤。由于氟尿苷口服给药时疗效不足,因此将其与替匹嘧啶混合以防止降解;该混合物被称为 TAS-102。TAS-102 单独使用时对肿瘤的抑制作用较小;然而,当与 AZD6738 联合使用时,观察到肿瘤抑制作用,表明 AZD6738 可能提高弱效药物的疗效。尽管 ATR 抑制剂对 p53 突变体有效,但本研究表明,这些抑制剂对 p53 野生型 HCT116 结直肠癌细胞系也有效。总之,AZD6738 与 FTD 的联合治疗增强了对肿瘤增殖的抑制作用。在未来,我们旨在研究 AZD6738 对难以治疗的 5-氟尿嘧啶耐药细胞系的增效作用。